
Biocept BIOC
Quarterly report 2023-Q2
added 06-06-2026
Biocept Cash Conversion Cycle 2011-2026 | BIOC
Annual Cash Conversion Cycle Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 78.1 | 29.9 | 51.8 | 124 | 421 | 151 | -43.7 | -67.8 | -516 | -24.1 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 421 | -516 | 20.3 |
Quarterly Cash Conversion Cycle Biocept
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117 | 197 | - | 241 | 222 | 27.2 | - | 46.5 | 71.5 | 27.4 | - | 95.8 | 1.17 K | 438 | 141 | 170 | 228 | 180 | 113 | 135 | 126 | 115 | 79.6 | 69.7 | 55.4 | 10.5 | -10.7 | -8.77 | -4.74 | 12.1 | -5.97 | -3.36 | 15.1 | -15.6 | -54.4 | 17.4 | -64.7 | -99.8 | 44.6 | -187 | -205 | -109 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.17 K | -205 | 87.2 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | ||
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
-2.46 K | $ 4.5 | -10.89 % | $ 5.99 M | ||
|
Fulgent Genetics
FLGT
|
51.8 | $ 18.5 | 1.04 % | $ 569 M | ||
|
Castle Biosciences
CSTL
|
31.6 | $ 21.08 | 4.77 % | $ 611 M | ||
|
Aspira Women's Health
AWH
|
1.01 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
2.11 | - | -61.36 % | $ 2.46 M | ||
|
ICON Public Limited Company
ICLR
|
52.5 | $ 151.82 | -0.28 % | $ 11.9 B | ||
|
Illumina
ILMN
|
147 | $ 160.03 | 1.26 % | $ 24.8 B | ||
|
Guardant Health
GH
|
79.6 | $ 130.12 | 4.19 % | $ 16.3 B | ||
|
CareDx, Inc
CDNA
|
51.5 | $ 22.75 | 3.64 % | $ 1.21 B | ||
|
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | ||
|
Interpace Biosciences
IDXG
|
62.9 | $ 1.74 | 3.57 % | $ 7.7 M | ||
|
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B | ||
|
NeoGenomics
NEO
|
82.4 | $ 11.44 | 4.47 % | $ 1.47 B | ||
|
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | ||
|
National Research Corporation
NRC
|
29.4 | $ 19.75 | 2.17 % | $ 442 M | ||
|
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
97.3 | $ 99.98 | -0.03 % | $ 6.75 B | ||
|
Charles River Laboratories International
CRL
|
65 | $ 189.85 | 1.83 % | $ 9.41 B | ||
|
Pacific Biosciences of California
PACB
|
185 | $ 1.37 | -0.72 % | $ 411 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
50.4 | $ 466.79 | 1.94 % | $ 13.5 B | ||
|
Exact Sciences Corporation
EXAS
|
42.5 | - | - | $ 19.8 B | ||
|
Mettler-Toledo International
MTD
|
66.4 | $ 1 162.79 | 2.1 % | $ 24 B | ||
|
Myriad Genetics
MYGN
|
49.3 | $ 4.54 | 3.42 % | $ 420 M | ||
|
Natera
NTRA
|
48.3 | $ 222.82 | 4.38 % | $ 30.5 B | ||
|
Personalis
PSNL
|
-1.89 | $ 9.75 | -2.89 % | $ 870 M | ||
|
Koninklijke Philips N.V.
PHG
|
89 | $ 26.5 | 2.63 % | $ 25.1 B | ||
|
Senseonics Holdings
SENS
|
36.1 | $ 7.43 | 4.21 % | $ 310 M | ||
|
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
-398 | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
172 | $ 2.05 | -0.92 % | $ 4.71 M | ||
|
Laboratory Corporation of America Holdings
LH
|
40.3 | $ 271.24 | 3.52 % | $ 22.6 B | ||
|
Twist Bioscience Corporation
TWST
|
83.6 | $ 70.06 | 0.03 % | $ 4.19 B | ||
|
Thermo Fisher Scientific
TMO
|
70 | $ 494.07 | 5.23 % | $ 186 B | ||
|
Trinity Biotech plc
TRIB
|
136 | $ 0.66 | -2.32 % | $ 237 M | ||
|
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
150 | $ 9.29 | 2.43 % | $ 2.01 B | ||
|
Waters Corporation
WAT
|
731 | $ 371.15 | 2.15 % | $ 22.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 204.53 | 3.71 % | $ 22.7 B |